As twin mental health and drug misuse crises kill thousands of people per week, the potential of psychedelic-assisted therapies "must be explored," urges a federal letter on behalf of the U.S. health secretary. President Joe Biden's administration "anticipates" that regulators will approve MDMA and psilocybin within the next two years for designated breakthrough therapies for PTSD and depression, respectively. The administration is "exploring the prospect of establishing a federal task force to monitor" the emerging psychedelic treatment ecosystem, according to the letter sent by Assistant Secretary for Mental Health and Substance Use. The move followed [the] introduction of a bipartisan bill, co-sponsored by Sens. Cory Booker, D-N.J., and Rand Paul, R-Ky., to force the DEA to stop barring terminally ill patients from trying controlled drugs which have passed early trials. The right to try experimental therapies has been enshrined in federal law since 2018, but the DEA currently blocks its use among people with late-stage cancer who wish to be treated with psilocybin, a Schedule I controlled substance. "Studies have shown that psilocybin produces substantial and sustained decreases in depression and anxiety among patients with life-threatening cancer," Booker wrote. "While typically terminally ill patients are allowed to access drugs that are in FDA clinical trials, they are barred from accessing Schedule I drugs, despite their therapeutic potential."